Multiple treatment cycles of high-dose intravenous immunoglobulin for chronic spontaneous urticaria.

摘要

To the Editor: We commend Mitzel-Kaoukhov et al for their study of high-dose intravenous imrnunoglobulin (IVIG) therapy for chronic spontaneous urticaria (CSU), in which patients received 2 g/kg across 2 days at monthly intervals (for 5 of 6 patients). Four of 6 patients had complete remission after 2 to 4 cycles, maintaining remission for 10 to 24 months without IVIG therapy. However, their favorable results contrast with our experience using IVIG in 3 patients with corticosteroid-dependent CSU. Our patients achieved only partial remission with subsequent relapse, similar to the results of Asero.